Further studies, including in vivo data that also take into account the complex interaction with other immune and non-immune cells expressing CD74 and targeted by milatuzumab, are needed to fully delineate the potential of anti-CD74 therapy in autoimmune diseases. Here, CD74 is linked to autoimmune disease.